Pasireotide

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hyperinsulinemic Hypoglycemia

Conditions

Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia

Trial Timeline

Mar 22, 2017 → Dec 22, 2017

NCT ID

NCT03103009

About Pasireotide

Pasireotide is a phase 1 stage product being developed by Novartis for Hyperinsulinemic Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03103009. Target conditions include Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03103009	Phase 1	Completed	Mar 22, 2017	Dec 22, 2017	Hyperinsulinemic Hypoglycemia
NCT02780882	Phase 2	Withdrawn	Dec 1, 2015	Jun 1, 2019	Ectopic ACTH Syndrome
NCT01617733	Phase 2	Terminated	Mar 1, 2011	Dec 1, 2015	Nelson Syndrome
NCT00698464	Phase 1	Completed	Jul 1, 2008	—	Hepatic Cirrhosis
NCT00434148	Phase 3	Completed	Dec 1, 2006	May 1, 2014	Cushing's Disease
NCT00446082	Phase 1	Completed	Jun 1, 2006	Nov 1, 2013	Carcinoid Tumor
NCT00171730	Phase 2	Completed	Aug 24, 2004	Dec 6, 2013	Acromegaly
NCT00171951	Phase 2	Completed	Aug 13, 2004	Jul 8, 2013	Cushing Disease

Competing Products

2 competing products in Hyperinsulinemic Hypoglycemia

See all competitors

Product	Company	Stage	Hype Score
Dasiglucagon + Placebo	Zealand Pharma	Phase 2	49
Glucagon RTU	Xeris Pharmaceuticals	Phase 2	47

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved